What is Kutapressin, and how is it related to Nexavir?

Kutapressin is the original name of the compound developed in the 1930s by Kremers Urban. Nexco Pharma acquired the rights to this same formulation in 2004 and rebranded it as Nexavir.

Is Nexavir FDA approved?

Nexavir holds FDA approval on a "grandfathered" basis, a designation given to formulations that predate current FDA testing protocols and have an established history of clinical use.

What is Nexavir made from?

Nexavir is a processed extract derived from porcine (pig) liver, yielding a mixture of small proteins known as polypeptides.

Is Nexavir safe to use?

Nexavir has a long-established safety profile built over 75 years of clinical use, with no significant safety concerns identified in that history. Individuals with pork allergies should not use Nexavir.

What are polypeptides, and why are they used in biologic medicine?

Polypeptides are short chains of amino acids found naturally in biological tissue. As a biologic compound rather than a synthetic one, they are of ongoing research interest for their potential anti-inflammatory and antiviral properties.

What is Nexco Pharma researching for the future?

Our research teams are working to isolate and characterize Nexavir's active polypeptides, with the long-term goal of developing a scalable, non-biological synthetic alternative.

How is a "grandfathered" FDA drug different from a newly approved one?

A grandfathered drug predates the FDA's modern testing and approval protocols. Its regulatory standing is supported by decades of documented real-world clinical use rather than a single formal trial process.

Post-Viral Recovery Research: Long COVID, CFS/ME & More

For patients navigating the complexities of chronic and post-viral conditions, some days feel like moving through a fog- not sick enough to easily explain it, but not well enough to ignore it. At Nexco Pharma, we're focused on exploring some of the world's most complex viral health challenges through time-tested, biologically derived science.

Expanding Therapeutic Horizons

Our research centers on leveraging decades of clinical experience alongside a growing body of modern science to support recovery in patients who need it most. We continue to study the applications of our core polypeptide formulation across several important areas of chronic and post-viral health:

Chronic & Post-Viral Syndromes - For more than 40 years, our formulation has been used by clinicians and patients navigating Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), as well as symptoms associated with viruses like Epstein-Barr (EBV) and Shingles. Patients living with post-viral fatigue often describe a search for options that go beyond simply managing symptoms and this is where decades of clinical experience with our formulation continues to inform ongoing research.
Emerging Viral Challenges - We're pioneering research into Long COVID and Hepatitis C. Early clinical observations have pointed to anti-viral and anti-inflammatory activity worth continued study, including isolated cases of improvement in liver enzyme markers during monitored use. As Long COVID and post-COVID syndrome continue to affect millions globally, the demand for well-studied, biologically derived recovery support options continues to grow.
Immunocompromised Care - Our formulation has also been used alongside standard HIV/AIDS treatment regimens, with ongoing interest in its potential supportive role for patients managing prolonged immune stress and elevated risk of opportunistic infection.

The Growing Need for Post-Viral Recovery Research

Post-viral syndromes including Long COVID, CFS/ME, and chronic EBV-related fatigue are increasingly recognized as significant, under-addressed areas of modern medicine. Symptoms like persistent fatigue, brain fog, and immune dysregulation can be difficult to treat with conventional approaches alone, which is why continued research into biologic, polypeptide-based therapeutics remains a meaningful area of focus for Nexco Pharma.

Two Formats. One Legacy of Care.

Patient comfort and accessibility guide our approach to innovation. While traditionally administered as an intramuscular injection, Nexco Pharma proudly manufactures a topical gel alternative in the USA. By offering multiple delivery formats, we aim to make this evidence-informed therapy easier to integrate into a patient's day-to-day life whether they prefer a clinical injectable or a more accessible topical option.

Nexco Pharma's manufacturing and research practices are backed by our certifications and regulatory credentials — learn more about the standards behind our formulations https://www.nexco-pharma.com/credential-certificates

FAQ

Our research spans Chronic Fatigue Syndrome (CFS/ME), Long COVID, Hepatitis C, Epstein-Barr Virus (EBV), Shingles, and supportive care for immunocompromised patients, including those on standard HIV/AIDS treatment regimens.

Nexco Pharma is actively researching the potential role of our polypeptide formulation in supporting recovery from Long COVID. This remains an area of ongoing study rather than a confirmed treatment outcome.

Our core formulation has more than 40 years of use history in supporting patients navigating Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).

The therapy is available as a traditional intramuscular injection (Nexavir) or as a topical gel manufactured in the USA (NexCream 75), offering patients flexibility based on comfort and accessibility.

Yes. For immunocompromised patients, our formulation has been used alongside standard HIV/AIDS treatment regimens as a complementary, supportive approach.

Conditions like Long COVID and CFS/ME affect a growing global population and often don't respond fully to conventional treatment approaches, making continued research into biologic and polypeptide-based therapeutics an important area of modern medicine.

Yes. Our Hepatitis C research has included clinical observations of liver enzyme marker improvement during monitored use, an area we continue to study further.